Skip to main content

Resmed Value Stock - Dividend - Research Selection

Resmed

ISIN: US7611521078 , WKN: 895878

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Q3 2024 Resmed Inc Earnings Call

2024-04-26
Q3 2024 Resmed Inc Earnings Call

ResMed Inc (RMD) Q3 2024 Earnings Call Transcript Highlights: Strong Financial Performance and ...

2024-04-26
ResMed Inc reports robust growth in revenue and earnings, alongside strategic discussions on market dynamics and future outlook.

Compared to Estimates, ResMed (RMD) Q3 Earnings: A Look at Key Metrics

2024-04-25
While the top- and bottom-line numbers for ResMed (RMD) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

ResMed Inc (RMD) Q3 Fiscal 2024 Earnings: Surpasses Analyst Expectations with Strong Growth

2024-04-25
Comprehensive Analysis of ResMed's Latest Financial Performance

ResMed Inc. 2024 Q3 - Results - Earnings Call Presentation

2024-04-25
The following slide deck was published by ResMed Inc.

ResMed Inc. (RMD) Q3 2024 Earnings Call Transcript

2024-04-25
ResMed Inc. (NYSE:NYSE:RMD) Q3 2024 Earnings Conference Call April 25, 2024 4:30 PM ETCompany ParticipantsAmy Wakeham - Chief Communications and Investor...

ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates

2024-04-25
ResMed (RMD) delivered earnings and revenue surprises of 10.94% and 1.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024

2024-04-25
Year-over-year revenue grows 7%, operating profit up 25%, non-GAAP operating profit up 23%Operating cash flows of $402 million Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2024. Third Quarter 2024 HighlightsAll comparisons are to the prior year period Revenue increased by 7% to $1.2 billion; up

ResMed: Fiscal Q3 Earnings Snapshot

2024-04-25
SAN DIEGO — SAN DIEGO — ResMed Inc. on Thursday reported fiscal third-quarter net income of $300.5 million. The San Diego-based company said it had profit of $2.04 per share. Earnings,...

Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?

2024-04-24
Here is a sneak peek into how the three major MedTech stocks, LH, EW and RMD, are expected to fare in their quarterly results slated to be released tomorrow.